Novartis, US regulators agree to malaria drug trial against Covid-19
Skip to main content
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
The Business Standard

Wednesday
February 01, 2023

Sign In
Subscribe
  • Home
  • Economy
    • Aviation
    • Bazaar
    • Budget
    • Industry
    • NBR
    • RMG
    • Corporates
  • Stocks
  • Analysis
  • World+Biz
  • Sports
  • Features
    • Book Review
    • Brands
    • Earth
    • Explorer
    • Fact Check
    • Family
    • Food
    • Game Reviews
    • Good Practices
    • Habitat
    • Humour
    • In Focus
    • Luxury
    • Mode
    • Panorama
    • Pursuit
    • Wealth
    • Wellbeing
    • Wheels
  • Epaper
  • More
    • Subscribe
    • Videos
    • Thoughts
    • Splash
    • Bangladesh
    • Supplement
    • Infograph
    • Archive
    • COVID-19
    • Games
    • Long Read
    • Interviews
    • Offbeat
    • Podcast
    • Quiz
    • Tech
    • Trial By Trivia
    • Magazine
  • বাংলা
WEDNESDAY, FEBRUARY 01, 2023
Novartis, US regulators agree to malaria drug trial against Covid-19

Coronavirus chronicle

Reuters
20 April, 2020, 12:05 pm
Last modified: 20 April, 2020, 12:23 pm

Related News

  • Flights canceled, at least 2 dead as ice storm freezes US
  • US, allies mark anniversary of Myanmar coup with fresh sanctions
  • US airlines cancel over 1,000 flights over winter storm
  • 10 people wounded in Florida mass shooting
  • US, S Korea to hold 'tabletop' exercises on nuclear threats

Novartis, US regulators agree to malaria drug trial against Covid-19

The decades-old medicine has received US Food and Drug Administration (FDA) emergency use authorisation for coronavirus disease, but so far there is no scientific proof it helps those afflicted

Reuters
20 April, 2020, 12:05 pm
Last modified: 20 April, 2020, 12:23 pm
The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020/Reuters
The company's logo is seen at a building of Swiss drugmaker Novartis in Rotkreuz, Switzerland, January 29, 2020/Reuters

Novartis has won the go-ahead from the US Food and Drug Administration to conduct a randomized trial of malaria drug hydroxychloroquine against Covid-19 disease, the Swiss drugmaker said on Monday, to see if it helps patients.

The decades-old generic medicine got FDA emergency use authorization this month for its unapproved use for coronavirus disease, but so far there is no scientific proof it works. There are currently no approved Covid-19 medicines.

Novartis plans to start recruiting 440 patients for its Phase III, or late-stage, trial within weeks at more than a dozen US sites. Results will be reported as soon as possible, the company added.

Use of the drug, also approved to treat lupus and rheumatoid arthritis, has soared after having been promoted by President Donald Trump, with some worried the administration's advocacy for an unproven medicine for Covid-19 has short-circuited the FDA's oversight process.

"We recognize the importance of answering the scientific question of whether hydroxychloroquine will be beneficial for patients with Covid-19 disease," said John Tsai, Novartis's top drug developer. "We mobilized quickly to address this question in a randomized, double-blind, placebo-controlled study."

Companies such as Novartis, Roche and Gilead Sciences are testing older medicines developed to treat other diseases, for signs they could be repurposed to tackle the coronavirus epidemic. Gilead just expanded a trial of its Ebola drug remdesivir.

Still, some fear the championing of hydroxychloroquine by Trump and others as a potential "game changer" against Covid-19 has overshadowed dangerous side effects like vision loss and heart problems. Novartis CEO Vas Narasimhan has also said the medicine is one of his biggest hopes against the viral epidemic.

There are several additional studies of hydroxychloroquine underway, including at the University of Washington and University of Minnesota, as well as work by the National Institutes of Health in the United States.

Novartis's Sandoz generics unit has pledged to donate 130 million doses of the medicine for use. Sanofi has also said it will donate 100 million doses of hydroxychloroquine to 50 countries.

Top News

Novartis / US / malaria drugs / Trial / Coronavirus / COVID-19

Comments

While most comments will be posted if they are on-topic and not abusive, moderation decisions are subjective. Published comments are readers’ own views and The Business Standard does not endorse any of the readers’ comments.

Top Stories

  • Will reform pledges to IMF work this time?
    Will reform pledges to IMF work this time?
  • Infographic: TBS
    How to redirect inward remittances to formal channels
  • Photo: TBS
    By-polls in BNP MPs' vacant seats: Candidate claims AL men intimidating voters in Chapainawabganj

MOST VIEWED

  • People walk outside wearing masks during the coronavirus disease (COVID-19) pandemic in the Harlem area of the Manhattan borough of New York City, New York, U.S., February 10, 2022. REUTERS/Carlo Allegri
    US to end Covid-19 emergency declarations on 11 May
  • A nurse prepares a shot for Jonathan Halter as the German embassy begins its roll out of BioNTech COVID-19 vaccines for German expatriates at a Beijing United Family hospital in Beijing, China January 5, 2023. REUTERS/Thomas Peter/File Photo
    Covid remains a public health emergency, says WHO
  • FIKE PHOTO: Medical staff moves a patient into a fever clinic at a hospital, as coronavirus disease (COVID-19) outbreaks continue in Shanghai, China, December 19, 2022. REUTERS/Aly Song
    China approves two domestically developed Covid drugs
  • People walk with their luggage at a railway station during the annual Spring Festival travel rush ahead of the Chinese Lunar New Year, as the coronavirus disease (COVID-19) outbreak continues, in Shanghai, China January 16, 2023. REUTERS/Aly Song
    Holiday trips within China surge after lifting of Covid curbs
  • Photo: Collected
    India launches world’s 1st intranasal Covid vaccine
  • A vial of the Pfizer-BioNTech coronavirus disease (COVID-19) booster vaccine targeting BA.4 and BA.5 Omicron sub variants is pictured at Skippack Pharmacy in Schwenksville, Pennsylvania, U.S., September 8, 2022. REUTERS/Hannah Beier
    US CDC still looking at potential stroke risk from Pfizer bivalent Covid shot

Related News

  • Flights canceled, at least 2 dead as ice storm freezes US
  • US, allies mark anniversary of Myanmar coup with fresh sanctions
  • US airlines cancel over 1,000 flights over winter storm
  • 10 people wounded in Florida mass shooting
  • US, S Korea to hold 'tabletop' exercises on nuclear threats

Features

An elderly couple's lonely battle to save Dhaka's trees

An elderly couple's lonely battle to save Dhaka's trees

1h | Panorama
Infographic: TBS

How to redirect inward remittances to formal channels

3h | Panorama
Photo: Bloomberg

How the 'madoffs of Manhattan' can unravel Gautam Adani's empire

1h | Panorama
Photo: Collected

Tips to incorporate sustainable construction

1d | Habitat

More Videos from TBS

Alka Yagnik guinness world record

Alka Yagnik guinness world record

11m | TBS Entertainment
Interest rate should be left to market

Interest rate should be left to market

16m | TBS Round Table
Adani’s shares fell sharply after allegation

Adani’s shares fell sharply after allegation

16h | TBS World
Why Messi was blocked on Instagram?

Why Messi was blocked on Instagram?

15h | TBS SPORTS

Most Read

1
Bapex calls candidates for job test 9 years after advert!
Bangladesh

Bapex calls candidates for job test 9 years after advert!

2
Photo: Collected
Energy

8 Ctg power plants out of production

3
Photo: Saqlain Rizve
Bangladesh

Bangladeshi university students identified as problematic users of Facebook, internet: Study

4
Photo: Collected
Court

Japanese mother gets guardianship of daughters, free to leave country

5
Fund cut as Dhaka's fast-track transit projects on slow spending lane
Infrastructure

Fund cut as Dhaka's fast-track transit projects on slow spending lane

6
The International Monetary Fund (IMF) logo is seen outside the headquarters building in Washington, U.S., September 4, 2018. REUTERS/Yuri Gripas/File Photo
Economy

IMF approves $4.7 billion loan for Bangladesh, calls for ambitious reforms

EMAIL US
[email protected]
FOLLOW US
WHATSAPP
+880 1847416158
The Business Standard
  • About Us
  • Contact us
  • Sitemap
  • Privacy Policy
  • Comment Policy
Copyright © 2023
The Business Standard All rights reserved
Technical Partner: RSI Lab

Contact Us

The Business Standard

Main Office -4/A, Eskaton Garden, Dhaka- 1000

Phone: +8801847 416158 - 59

Send Opinion articles to - [email protected]

For advertisement- [email protected]